Today, the value of this approach is widely recognised even by most pharmaceutical companies, a number of which – including Sanofi, Roche and Genentech, Bayer, and Merck KgaA – have partnered with ...

With additional patient-centric data, compute power, and an exciting new focus for its Bayer collaboration, the company is accelerating the shift of biotech to techbioSALT LAKE CITY, Nov. 09, 2023 ...

Trained on Recursion’s BioHive-2 and accelerated by NVIDIA, the model achieves near-FEP accuracy at speeds up to 1,000× faster, marking one of the most significant advances yet in AI-enabled drug ...

We recently published 12 Best Healthcare Stocks to Buy Under $30. Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of the ...

Recursion Pharmaceuticals has a prescription for high drug costs: AI and 25 petabytes of data Growing interest in AI-powered drug discovery draws some big investors–and regulatory questions ...

Recursion plans to present data from this trial at a forthcoming medical conference and intends to submit these data for publication in a peer reviewed scientific journal.

Salt Lake City, UT, April 22, 2025 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, will present preliminary data ...